• Home
  •  Hyperkalaemia in Cardiorenal Disease – A Case Based Discussion
  • Home
  •  Hyperkalaemia in Cardiorenal Disease – A Case Based Discussion

Hyperkalaemia in Cardiorenal Disease – A Case Based Discussion

Topic:
  • CKD
  • Heart Failure
  • Prevention

Available Credit:

  • Not accredited

Course Published On:

Course Expiry Date:

Register now Log in
Hyperkalaemia in Cardiorenal Disease – A Case Based Discussion

Overview

A renowned international faculty moderated by Prof James Burton explore emerging data and the changing landscape of medical management of hyperkalaemia.

 

RAASi therapy serves part of the foundational treatment for heart failure and chronic kidney disease, but it is also a risk factor for hyperkalaemia. This conundrum poses challenges to physicians managing cardio-renal patients.

 

Support Statement

This programme is supported by an unrestricted educational grant from AstraZeneca.

 

Target Audience

  • Nephrologists
  • Cardiologists
  • Heart Failure Specialists
  • Nurses
  • GPs
  • Pharmacists
  • Primary Care Practitioners
  • HCPs

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Explain the relationship between sub-optimal RAASi therapy and poor cardio-renal outcomes
  • Identify patients who would benefit from anti-hyperkalaemia medications
  • Select appropriate anti-hyperkalaemia treatments across a range of patient profiles
  • Adopt anti-hyperkalaemia medications as an approach to prolong optimal RAASi therapy
  • Summarise current guideline recommendations on the use of potassium binding agents
Register now Log in

Module

Title

Duration

Speakers
Session 1 Recap on Patient Case Studies 10m 43s James Burton Shelley Zieroth
Session 2 Risk Factors for Hyperkalaemia 12m 52s James Burton
Session 3 Real-world HK Management Practices 21m 45s Shelley Zieroth
Session 4 Towards an Aligned Treatment Approach in Cardiorenal Patients 12m 14s James Burton
Session 5 Managing Hyperkalaemia to Facilitate RAASi: Best Practices in Cardiorenal Patients 19m 56s Andrew Frankel
Session 6 Clinical Impact of Suboptimal RAASi 10m 24s Clara Bonanad Lozano
Session 7 Clinical Questions Answered and Close 6m 30s James Burton Shelley Zieroth Clara Bonanad Lozano Andrew Frankel
Session 1.

Recap on Patient Case Studies

Duration: 10m 43s

Speakers: James Burton Shelley Zieroth

Session 2.

Risk Factors for Hyperkalaemia

Duration: 12m 52s

Speakers: James Burton

Session 3.

Real-world HK Management Practices

Duration: 21m 45s

Speakers: Shelley Zieroth

Session 4.

Towards an Aligned Treatment Approach in Cardiorenal Patients

Duration: 12m 14s

Speakers: James Burton

Session 5.

Managing Hyperkalaemia to Facilitate RAASi: Best Practices in Cardiorenal Patients

Duration: 19m 56s

Speakers: Andrew Frankel

Session 6.

Clinical Impact of Suboptimal RAASi

Duration: 10m 24s

Speakers: Clara Bonanad Lozano

Session 7.

Clinical Questions Answered and Close

Duration: 6m 30s

Speakers: James Burton Shelley Zieroth Clara Bonanad Lozano Andrew Frankel

Chair

James Burton

University of Leicester, UK

Prof James Burton is Honorary Consultant Nephrologist and Professor of Renal Medicine and Associate Dean for Clinical Research at the University of Leicester, Leicester, UK.

View full profile

Panelist

Shelley Zieroth

St Boniface Hospital, Winnipeg, CA

Dr Shelley Zieroth is Professor at the College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, as well as Director of the Heart Failure and Heart Transplant Clinics at St Boniface Hospital in Winnipeg, Canada.

View full profile

Clara Bonanad Lozano

University Clinical Hospital of Valencia, Valencia, ES

Dr Clara Bonanad Lozano is a cardiologist at the University Clinical Hospital of Valencia, ES and president of the Association of Geriatric Cardiology of the Spanish Society of Cardiology.

View full profile

Andrew Frankel

Imperial College Healthcare NHS, London, UK

Dr Andrew Frankel has been working as a consultant nephrologist at Imperial College Healthcare NHS trust since 1995. He has experience in managing all aspects of kidney disease but has a particular interest in relation to the management of diabetes in the context of kidney disease.

View full profile
This course is not accredited
Register now Log in